Instructions for Credit - There is no fee for this activity. To receive credit for this CME/CE activity, review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for up to 1.0 continuing education credit. Please retain a copy of the certificate for your records.
Physicians, advance practice providers, and nurses involved in the care of adolescents and young adults with hematologic malignancies.
At the conclusion of this program, participants will be able to:
- Describe common adolescent and young adult (AYA) blood cancers
- Identify signs and symptoms of AYA blood cancer and diagnostic tests
- Explain treatments, including the role of clinical trials
- Discuss management of short- and long-term effects, including fertility challenges
- Address unique considerations for AYA's (e.g., sexuality and intimacy, finances and health insurance)
- Discuss strategies to enhance provider communication with AYA's to help them navigate challenges
Leidy L. Isenalumhe, MD, MS
Assistant Member, Malignant Hematology
Director of Clinical Operations, Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Physician Credit Designation
The Treating Adolescents and Young Adults with Blood Cancer webinar is approved for up to 1.0 prescribed credit by the American Academy of Family Physicians (AAFP). Please complete the evaluation to obtain enduring CME credit.
Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.
Social Work Credit Designation
There are no CE credits for social work for this program.
All continuing education credits are provided free of charge.
Disclosure of Conflicts of Interest:
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker's bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Clinical Directors Network, Inc. and The Leukemia & Lymphoma Society for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Clinical Directors Network, Inc. and The Leukemia & Lymphoma Society, the accredited providers for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity during the past 12 months.
Dr. Isenalumhe has no affiliations to disclose.
The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
An active internet connection with Web browser is required to view this activity.
Estimated time to complete activity: 1.0 hour
Date of initial release: June 16, 2021
Valid for CME credit through: June 16, 2022
Valid for CE credit through: June 16, 2022
For questions, concerns, or for assistance for people with disabilities or grievances, please contact ProfEducation@LLS.org